Navigation Links
DrugRisk Alert: Pradaxa Leads Study of Complication Reports to FDA
Date:10/26/2013

Dallas, TX (PRWEB) October 26, 2013

The prescription drug resource center DrugRisk.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A recently published study identified the drug as the most often reported for serious side effects like internal bleeding*.

The news comes on the same day as a federal court disclosed the number of lawsuits alleging internal bleeding injuries has again grown**.

The DrugRisk center is a free resource for those taking popular prescription drugs. By providing the latest product recalls, safety alerts, research and litigation news, patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

Pradaxa is a blood thinner approved by the FDA in 2010 as a stroke preventative for patients with atrial fibrillation. Experts disagree, however, about its risks for internal bleeding.

The FDA has advised Pradaxa is no more dangerous than traditional blood thinner warfarin***. Others, like the Institute for Safe Medication Practices, have warned that patients may be nearly 5 times as likely to die from Pradaxa bleeding than from warfarin bleeding****. A study this year from the Netherlands also suggested patients taking blood thinners like Pradaxa may be 55% more likely to suffer internal bleeding*****.

Now. DrugRisk has learned that the latest study from the Institute for Safe Medication Practices found Pradaxa ranked highest for number of complaints to the FDA last year, with 683 reports of bleeding*.

A growing number of patients have also filed a Pradaxa lawsuit alleging internal bleeding, leading to the consolidation of cases in a special federal multidistrict litigation court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

DrugRisk has added the latest court records from the Judicial Panel on Multidistrict Litigation, which show the number of cases filed has increased from 1,470 on September 11th to 1,643 on October 17, a rise of nearly 12% in less than a month**.

Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.

*Institute for Safe Medication Practices, 10/17/13; ismp.org/quarterwatch/pdfs/2012Q4.pdf
**Judicial Panel on Multidistrict Litigation, 10/17/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf
***FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
****Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
*****Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext

Read the full story at http://www.prweb.com/releases/2013-pradaxa/gastrointestinal-bleeding/prweb11271909.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Alerts of New Rise In Mirena Lawsuits Alleging Uterine Damage
2. DrugRisk Updates with Latest Case Numbers Since Januvia Lawsuits Sent to MDL Court
3. DrugRisk Update: Byetta Lawsuits Headed to Special Federal Court
4. DrugRisk Update: Januvia Lawsuits Alleging Cancer Headed to Federal Court
5. DrugRisk Update: Latest Court Order Moves Mirena Lawsuits Forward
6. DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
7. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
8. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
9. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
10. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
11. DrugRisk Announces Drop in Yaz Lawsuits As Bayer Commits $1.5 Billion to Settlements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: